(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs PAC 1 (Primary)
- Indications Haematological malignancies; Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Vanquish Oncology
- 10 Oct 2017 Status changed from active, no longer recruiting to recruiting.
- 17 May 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology